Call buyers bet that Bristol-Myers will get better soon
Bristol-Myers Squibb (BMY) is getting some attention from call buyers Thursday. So far, 3,644 contracts of the Oct. 57 call have changed hands, against open interest of 54 contracts. Today’s volume has been predominantly in the high side of the bid-ask spread, indicating that these new contracts are likely being bought to open.
Already a member?
Login to see your Unusual Options Activity Trade Idea.
Not yet a member?
You can receive four timely bull-put credit spreads each market day by joining our InvestorsKeyhole Daily Trade Alerts Service. Our analysts scour the news looking for unusual options activity, how insiders are trading, and breaking news, and publish trades accordingly.
Become A Member
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Co discovers, develops, and markets drugs for various indications, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is leading in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs.